Mizuho Has Lowered Expectations for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price objective reduced by investment analysts at Mizuho from $175.00 to $155.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the medical research company's stock. Mizuho's price objective would suggest a potential upside of 46.81% from the stock's current price.

A number of other research firms have also recently issued reports on CRL. UBS Group restated a "neutral" rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $182.00.

Remove Ads

Charles River Laboratories International Trading Up 5.8 %

CRL traded up $5.83 during trading on Wednesday, reaching $105.58. The company had a trading volume of 1,415,709 shares, compared to its average volume of 861,054. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business has a 50 day simple moving average of $156.71 and a 200-day simple moving average of $176.86. The stock has a market cap of $5.19 billion, a P/E ratio of 703.87, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the previous year, the company earned $2.46 EPS. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Patriot Financial Group Insurance Agency LLC grew its position in shares of Charles River Laboratories International by 12.8% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,706 shares of the medical research company's stock valued at $257,000 after purchasing an additional 194 shares during the period. Impact Capital Partners LLC grew its stake in Charles River Laboratories International by 12.2% during the 1st quarter. Impact Capital Partners LLC now owns 2,567 shares of the medical research company's stock valued at $386,000 after acquiring an additional 280 shares in the last quarter. Veracity Capital LLC lifted its stake in Charles River Laboratories International by 3.4% in the 1st quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock worth $496,000 after purchasing an additional 107 shares in the last quarter. Heritage Family Offices LLP boosted its holdings in shares of Charles River Laboratories International by 10.0% during the 1st quarter. Heritage Family Offices LLP now owns 1,689 shares of the medical research company's stock worth $254,000 after purchasing an additional 153 shares during the last quarter. Finally, Mitchell & Pahl Private Wealth LLC grew its position in shares of Charles River Laboratories International by 6.7% in the first quarter. Mitchell & Pahl Private Wealth LLC now owns 3,843 shares of the medical research company's stock valued at $578,000 after purchasing an additional 240 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).